George C Prendergast
Overview
Explore the profile of George C Prendergast including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
6474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van N, Zhang K, Wigmore R, Kennedy A, DaSilva C, Huang J, et al.
Nat Commun
. 2023 Nov;
14(1):7363.
PMID: 37963876
Environmental factors are the major contributor to the onset of immunological disorders such as ulcerative colitis. However, their identities remain unclear. Here, we discover that the amount of consumed L-Tryptophan...
2.
Thomas S, Prendergast G
Front Pharmacol
. 2023 Jul;
14:1183932.
PMID: 37521457
Longer lifespan produces risks of age-associated neurodegenerative disorders such as Alzheimer's disease (AD), which is characterized by declines in memory and cognitive function. The pathogenic causes of AD are thought...
3.
Thomas S, Dilbarov N, Kelly J, Mercogliano G, Prendergast G
Sci Rep
. 2023 Jul;
13(1):11802.
PMID: 37479833
Ulcerative colitis (UC) is an idiopathic disease of the large intestine linked to high fat-high protein diets, a dysbiotic microbiome, and a metabolome linked to diet and/or aberrant circadian rhythms...
4.
Hill B, Calder A, Flemming J, Guo Y, Gilmore S, Trofa M, et al.
Mol Carcinog
. 2023 Jul;
62(9):1428-1443.
PMID: 37401875
Therapy using anti-PD-1 immune checkpoint inhibitors (ICI) has revolutionized the treatment of many cancers including head and neck squamous cell carcinomas (HNSCC), but only a fraction of patients respond. To...
5.
Muller A, Mondal A, Dey S, Prendergast G
Front Oncol
. 2023 May;
13:1165298.
PMID: 37182174
In parallel with the genetic and epigenetic changes that accumulate in tumor cells, chronic tumor-promoting inflammation establishes a local microenvironment that fosters the development of malignancy. While knowledge of the...
6.
Muller A, Thomas S, Prendergast G
Cancer J
. 2023 Jan;
29(1):34-37.
PMID: 36693156
Vaccine strategies for cancer differ from infectious disease in focusing mainly on clearing rather than preventing disease. Here we survey general vaccine strategies and combination therapy concepts being investigated for...
7.
Thomas S, Mercogliano G, Prendergast G
PLoS One
. 2022 Nov;
17(11):e0276910.
PMID: 36322599
Ulcerative colitis (UC) is a common chronic disease of the large intestine. Current anti-inflammatory drugs prescribed to treat this disease have limited utility due to significant side-effects. Thus, immunotherapies for...
8.
Merlo L, Peng W, DuHadaway J, Montgomery J, Prendergast G, Muller A, et al.
J Immunol
. 2021 Dec;
208(3):571-581.
PMID: 34965962
IDO2 is one of two closely related tryptophan catabolizing enzymes induced under inflammatory conditions. In contrast to the immunoregulatory role defined for IDO1 in cancer models, IDO2 has a proinflammatory...
9.
Brochez L, Kruse V, Schadendorf D, Muller A, Prendergast G
Front Immunol
. 2021 Dec;
12:789473.
PMID: 34938297
No abstract available.
10.
Schultz C, McCarthy G, Nerwal T, Nevler A, DuHadaway J, McCoy M, et al.
Mol Cancer Ther
. 2021 Aug;
20(11):2166-2176.
PMID: 34413127
Pancreatic ductal adenocarcinoma (PDAC) is a lethal aggressive cancer, in part due to elements of the microenvironment (hypoxia, hypoglycemia) that cause metabolic network alterations. The FDA-approved antihelminthic pyrvinium pamoate (PP)...